The American Pharmacist Modern said this Thursday, August 5, 2021, that a third dose of his vaccine against COVID-19 before the end of the year due to the probable increase in infections caused by the Delta variant.
We recommend you: Germany will apply in September COVID-19 booster vaccine from Pfizer or Moderna
In an investor presentation related to its quarterly results, Modern He broke down his latest data and strategy regarding the third booster dose, on which he is studying the most effective amount of product.
“We believe that a booster (dose 3) will probably be necessary this fall (northern hemisphere), particularly due to delta,” said the company, which has obtained promising protection data with a dose of 50 micrograms and expects that of another dose of 100 .
Modern He opined that “the increased infection force resulting from Delta,” “fatigue” from prevention actions, and “seasonal effects,” such as spending more time indoors, “will lead to an increase in breakthrough infections in vaccinated people.”
According to the document, the firm has expectations that 93% efficacy against infections of COVID-19 that has been proven after the two-dose regimen begins to “decline” after six months “and eventually impacts” those results.
“Given this intersection, we believe that a third booster dose will likely be necessary before winter (from the northern hemisphere),” he insisted.
Modern that third booster dose is still under study, which was given with a 50 microgram amount of product to a group of patients six months after receiving the second dose.
According to the first data published today, the levels of neutralizing antibodies of COVID-19 “They had decreased significantly before the boost after about six months” in the patients.
The third dose “boosted” their antibody levels to exceed the efficacy obtained in the original clinical trial of the vaccine, and also in a “similar” way between different age groups, especially in adults over 65 years of age.
Moderna today reported earnings of $ 4,001 million through June, achieving the first six-month net profit in its history, thanks to the sales of its vaccine against COVID-19, for which it entered 5.900 million dollars.
With information from EFE